Development of a small diameter vascular prosthesis foro coronary artery bypass grafting with a capacity of collateral formation due to angiogenesis because of endogenous cytokines

开发用于冠状动脉旁路移植术的小直径血管假体，该假体具有由于内源性细胞因子的血管生成而形成侧支循环的能力

• 批准号: 09470287
• 负责人: ENDO Masahiro
• 金额: $ 5.12万
• 依托单位: Tokyo Women's Medical University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1999
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09470287/
• 关键词: Small diameter vascular prosthesis; Graft; Endogenous; Cytokines; Endothelialization; CABG; Collateral formation; endogenous; angiogenesis; 小口径; ハイブリット; 抗血栓性; 冠動脈; 血管新生

Antithrombogenicity is one of the most important factors for development of small diameter vascular prosthesis in the coronary artery position. To obtain permanent anthrombogenicity, rapid endothelialization is important for conduits for coronary artery bypass grafting (CABG). Endogenous cytokines including basic fibroblast growth factor (bFGF) works for angiogenesis. Tissue fragmented vascular grafts were developed using autologous connective tissue. From vaso vasorum, endothelialization started on the lumen. From the fragments, production of endogenous cytokines was expected. Angiogenesis was also studied in a rabbit ear chamber model in this term. Angiogenesis occurred from venous side. With endogenous cytokines, it took 3 weeks for 3 mm in the chamber. It was concluded that angiogenesis due to endogenous cytokines may work for treatment of ischemic heart disease, as endothelialization of bypass graft, and as collateral formation.

抗血栓形成是冠状动脉位置小直径血管假体开发的最重要因素之一。为了获得永久性的血栓形成，快速内皮化对于冠状动脉旁路移植术（CABG）的导管非常重要。包括碱性成纤维细胞生长因子 (bFGF) 在内的内源性细胞因子可促进血管生成。使用自体结缔组织开发组织碎片血管移植物。从血管滋养管开始，内皮化在管腔上开始。预计从这些片段中会产生内源性细胞因子。本学期还在兔耳室模型中研究了血管生成。血管生成从静脉侧发生。对于内源性细胞因子，在腔室中需要 3 周时间才能达到 3 毫米。结论是，内源性细胞因子引起的血管生成可能有助于治疗缺血性心脏病，作为旁路移植物的内皮化和侧支循环形成。

项目成果

Nishida H, Akazawa T, Nishinaka T, Aomi S, Endo M, Koyanagi H.: "Afterload-dependent flow fluctuation of centrifugal pump : shoul it be actively fixed?"Artif Organs.. 22. 362-365 (1998)

Nishida H、Akazawa T、Nishinaka T、Aomi S、Endo M、Koyanagi H.：“离心泵的后负载相关流量波动：应该主动修复吗？”Artif Organs.. 22. 362-365 (1998)

Kitamura M, Uwabe K, Hirota J, Kawai A, Endo M, Koyanagi H.: "Minimally invasive cardiac surgery in the adult : surgical instruments, equipment, and techniques."Artif Organs.. 22. 765-768 (1998)

Kitamura M、Uwabe K、Hirota J、Kawai A、Endo M、Koyanagi H.：“成人微创心脏手术：手术器械、设备和技术。”Artif Organs.. 22. 765-768 (1998)

冨澤康子 ほか: "人工血管内皮化促進のためのin vivo組織培養における内因性サイトカインの活性化" 人工臓器. 26. 699-703 (1997)

Yasuko Tomizawa 等人：“体内组织培养中内源性细胞因子的激活以促进人造血管的内皮化”Artificial Organs。

Kitamura M, Aoki S. Hachida M. Nishida H, Endo M. Koyanagi H.: "Current strategy of temporary circulatory support for severe cardiac failure after operation."Ann Thorac Surg.. 68. 662-665 (1999)

Kitamura M、Aoki S. Hachida M. Nishida H、Endo M. Koyanagi H.：“手术后严重心力衰竭临时循环支持的当前策略。”Ann Thorac Surg.. 68. 662-665 (1999)

Nishida H, Aomi S, Tomizawa Y, Endo M, Koyanagi H, Nojiri C, Oshiyama H, Kido T, Yokoyama K.: "Comparative study of biocompatibility between the open circuit and closed circuit in"Artif Organs.. 23. 547-551 (1999)

Nishida H、Aomi S、Tomizawa Y、Endo M、Koyanagi H、Nojiri C、Oshiyama H、Kido T、Yokoyama K.：“Artif Organs 中开路和闭路生物相容性的比较研究.. 23. 547-